Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.
Surgery
; 152(3 Suppl 1): S152-6, 2012 Sep.
Article
em En
| MEDLINE
| ID: mdl-22763259
ABSTRACT
One major barrier in the development of pancreas cancer therapeutics is the selective delivery of the drugs to their cellular targets. We have previously developed several sigma-2 ligands and reported the discovery of a component of the receptor for these ligands. Several sigma-2 ligands have been shown to trigger apoptosis in pancreas cancer cells. More importantly, sigma-2 ligands are internalized rapidly by the cancer cells and are capable of delivering other small-molecule therapeutics. Here we review sigma-2 ligands and conjugates as a potential novel therapy suitable for investigation in patients with pancreatic cancer.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Receptores sigma
/
Terapia de Alvo Molecular
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article